Skip to content
172717271727

Drawing based on the label description. No photo yet.

1727 pill

Pill with imprint 1727 is white, oval, 11 mm and has been identified as Tofacitinib 22 mg. It is used for rheumatoid arthritis. It is supplied by Zydus Lifesciences Limited.

Tofacitinib 22 mg

Imprint
1727
Strength
22 mg
Used for
Rheumatoid arthritis
Color
White
Shape
Oval
Size
11 mm
Score
No score line
Form
Tablet, film coated, extended release
Manufacturer
Zydus Lifesciences Limited
Drug class
Cancer medicine (kinase inhibitor)
NDC
70771-1628, 70771-1628-3, 70771-1628-9, 70710-1727, 70710-1727-3, 70710-1727-9

Source: the official drug label on DailyMed (US National Library of Medicine). Last checked .

Report a mistake

Please do not include personal health information. For questions about your medicine, ask a pharmacist.

All Tofacitinib pills and guides

What is Tofacitinib used for?

Tofacitinib is used for rheumatoid arthritis.

Medicine type
Cancer medicine (kinase inhibitor)
Official uses from the US prescribing label

Rheumatoid Arthritis

Tofacitinib extended-release tablets are indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA), who have had an inadequate response or intolerance to one or more TNF blockers.

Limitations of Use

Use of tofacitinib extended-release tablets in combination with biologic disease-modifying antirheumatic drugs (DMARDs) or with potent immunosuppressants such as azathioprine and cyclosporine is not recommended.

Psoriatic Arthritis

Tofacitinib extended-release tablets are indicated for the treatment of adults with active PsA who have had an inadequate response or intolerance to one or more TNF blockers.

Limitations of Use

Use of tofacitinib extended-release tablets in combination with biologic DMARDs or with potent immunosuppressants such as azathioprine and cyclosporine is not recommended.

Ankylosing Spondylitis

Tofacitinib extended-release tablets are indicated for the treatment of adult patients with active ankylosing spondylitis (AS), who have had an inadequate response or intolerance to one or more TNF blockers.

Limitations of Use

Use of tofacitinib extended-release tablets in combination with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine is not recommended.

From the FDA-approved label on DailyMed (published Oct 05, 2026).

Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.

Is this your pill? Check every detail

  • Your pill shows 1727.
  • It is white, oval, 11 mm.
  • Its score line and coating match the details on this page.
  • It came from a pharmacy package that names the same drug.

Ingredients

Active: Tofacitinib Citrate

Inactive: Ethylcellulose (7 Mpa.s), Ferrosoferric Oxide, Hypromellose 2208 (100 Mpa.s), Hypromellose 2208 (4000 Mpa.s), Hypromellose 2910 (6 Mpa.s), Lactose Monohydrate, Magnesium Stearate, Polyethylene Glycol 4000, Propylene Glycol, Shellac, Sodium Lauryl Sulfate, Titanium Dioxide

Also distributed by

Zydus Pharmaceuticals USA Inc.

Pills that look similar but are different drugs

Same color and shape, different medicine. This is why the imprint matters.

Other Tofacitinib pills